Skip to Main Content

Neuropathology Core

The Neuropathology Core is co-led by Drs. Anita Huttner MD, Director of Neuropathology, Pathology, and Caroline Zeiss PhD, Chief of Pathology, Comparative Medicine, and fulfills multiple important roles within the Yale Alzheimer's Disease Research Center (ADRC).

The Neuropathology Core (NP Core) provides an infrastructure for postmortem recovery and analysis of tissues from participants evaluated and followed in the Clinical Core. Detailed neuropathological assessments form the basis for the validation of clinical diagnoses, candidate antemortem biomarkers and imaging characteristics, and help uncover potential co-existing neurodegenerative or vascular disease processes. In addition, the NP Core serves as a biorepository for tissue samples and cell lines. Through systematic banking, cataloguing and distribution of well-annotated tissue samples, the NP Core forms a key component within the Yale ADRC. It enhances clinical, genetic, imaging, and biomarker research of ADRC investigators by enabling pathological correlations and tissue-based research throughout the broader research community.


  • Albert E. Kent Professor of Neuroscience and Professor of Psychology; Member, Kavli Institute of Neuroscience at Yale University

    Dr. Arnsten is an international expert on the molecular regulation of higher cortical circuits, and a member of the National Academy of Medicine. She received her B.A. in Neuroscience from Brown University in 1976 (where she created the Neuroscience major), and her Ph.D. in Neuroscience from UCSD in 1981. She did post-doctoral research with Dr. Susan Iversen at Cambridge University in the UK, and with Dr. Patricia Goldman-Rakic at Yale. Dr. Arnsten's research examines the neural basis of higher cognition. Her work has revealed that the newly evolved cortical circuits that underlie higher cognition are uniquely regulated at the molecular level, conferring vulnerability in mental illness and age-related cognitive disorders such as Alzheimer's Disease. Arnsten's research has led to new treatments for cognitive disorders in humans, including the successful translation of guanfacine (IntunivTM) for the treatment of ADHD and related prefrontal cortical disorders.